Association of denosumab with serum cytokines, chemokines, and bone-related factors in patients with rheumatoid arthritis: A post hoc analysis of a multicentre, open-label, randomised, parallel-group study

Author:

Iwamoto Naoki1,Sato Shuntaro2,Furukawa Kaori1,Michitsuji Toru1,Shiraishi Kazuteru3,Watanabe Kounosuke3,Chiba Ko3,Osaki Makoto3,Kawakami Atsushi1

Affiliation:

1. Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences , Nagasaki, Japan

2. Clinical Research Center, Nagasaki University Hospital , Nagasaki, Japan

3. Department of Orthopedic Surgery, Nagasaki University Graduate School of Biomedical Sciences , Nagasaki, Japan

Abstract

ABSTRACT Objectives To clarify changes in serum cytokines, chemokines, and bone-related factors during denosumab treatment in rheumatoid arthritis (RA) patients. Methods This was a post hoc analysis of a multicentre, open-label, randomised, parallel-group study. Patients were randomly assigned to continue treatment with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) plus receive treatment with denosumab (csDMARDs plus denosumab group) or to continue treatment with csDMARD therapy alone for 12 months. Serum biomarker levels were measured at baseline and at 6 and 12 months. Results Baseline and 6-month data from the csDMARDs plus denosumab (n = 22) and csDMARD therapy alone (n = 22) groups were analysed. Statistically significant changes from baseline were seen: Dickkopf-related protein 1 decreased at 6 and 12 months (both groups); osteopontin decreased at 6 months in the csDMARDs plus denosumab group; osteopontin and soluble CD40 ligand increased at 6 and 12 months in the csDMARD therapy alone group; osteocalcin decreased at 6 and 12 months, epidermal growth factor decreased at 12 months, and macrophage-derived chemokine decreased at 6 months in the csDMARDs plus denosumab group; and interferon gamma-induced protein-10 increased at 12 months in the csDMARD therapy alone group. Conclusions Denosumab may inhibit bone destruction by suppressing bone-related factors/chemokines.

Publisher

Oxford University Press (OUP)

Reference49 articles.

1. Rheumatoid arthritis: a brief overview of the treatment;Bullock;Med Princ Pract,2018

2. Bone erosions in rheumatoid arthritis: recent developments in pathogenesis and therapeutic implications;Panagopoulos;J Musculoskelet Neuronal Interact,2018

3. Rheumatoid arthritis;Tanaka;Inflamm Regen,2020

4. A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study;Hirata;Rheumatology (Oxford),2013

5. Biomarkers as a treatment guide in rheumatoid arthritis;Takeuchi;Clin Immunol,2018

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3